Recruiting
Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation
NCT07615049· Phase 3· SWOG Cancer Research Network· Source
Contact: Sibo Tian (principal investigator)
Recruiting
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
NCT07748208· Phase 2· Hoffmann-La Roche· Source
Recruiting
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
NCT07859722· Emory University· Source
Contact: Ardith Deshay
Recruiting
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
NCT07147231· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Olumide B. Gbolahan (principal investigator)
Recruiting
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· Phase 3· NRG Oncology· Source
Contact: Jose A. Monteiro de Oliveira Novaes (principal investigator)
Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
NCT07003295· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jonathon B. Cohen (principal investigator)
Recruiting
ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)
NCT07559903· Emory University· Source
Contact: Daniel Gold, MD
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
NCT06980038· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jose A. Monteiro de Oliveira Novaes (principal investigator)
Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940· Phase 3· SWOG Cancer Research Network· Source
Contact: Olumide B. Gbolahan (principal investigator)
Recruiting
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
NCT07195734· Phase 2· National Cancer Institute (NCI)· Source
Contact: Jennifer Gross (principal investigator)
Recruiting
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
NCT07405476· Phase 2· Emory University· Source
Contact: Olumide B. Gbolahan, MBBS, MSc
Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NCT07166406· Phase 3· NRG Oncology· Source
Contact: Soumon Rudra (principal investigator)
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· Phase 3· National Cancer Institute (NCI)· Source
Contact: Kristen Starbuck (principal investigator)
Recruiting
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
NCT07174570· Phase 2· Emory University· Source
Contact: Kathleen Coleman
Recruiting
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT06324240· Phase 1· Emory University· Source
Contact: Deborah Omoyege
Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
NCT06524544· Phase 3· National Cancer Institute (NCI)· Source
Contact: Jacqueline T. Brown (principal investigator)
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225· Phase 1· Pfizer· Source
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
NCT07061977· Phase 3· National Cancer Institute (NCI)· Source
Contact: Sarah Dilley (principal investigator)
Recruiting
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source
Contact: Seth Concors (principal investigator)
Recruiting
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
NCT07150546· Phase 1· Emory University· Source
Contact: Lisa Metzger
Recruiting
Dysphagia Study Using Novel Microphone Device
NCT07251140· Emory University· Source
Contact: Hyojung Choo, PhD
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· Phase 3· NRG Oncology· Source
Contact: Natalie A. Ridge (principal investigator)
Recruiting
IVUS CHIP UPP Registry
NCT06625801· ECRI bv· Source
Contact: Chantal Bakker
Recruiting
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
NCT07140679· Phase 2· Emory University· Source
Contact: Jalpa Patel
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· Phase 3· NRG Oncology· Source
Contact: Pretesh R. Patel (principal investigator)
Active, not recruiting
Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer
NCT06732401· Phase 3· National Cancer Institute (NCI)· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
CARE-D-FOOT-Nav Pilot
NCT07143175· Emory University· Source
Contact: Marcos Schechter, MD
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582· Phase 2· National Cancer Institute (NCI)· Source
Contact: Kamran Salari (principal investigator)
Recruiting
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924· Phase 3· Canadian Cancer Trials Group· Source
Contact: Bradley C. Carthon (principal investigator)
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584· Phase 2/3· SWOG Cancer Research Network· Source
Contact: Jennifer W. Carlisle (principal investigator)
Recruiting
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
NCT06868433· Phase 1· Emory University· Source
Contact: Nilaab Meer
Recruiting
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
NCT06952660· Phase 4· Pfizer· Source
Recruiting
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
NCT06439836· Phase 1· National Cancer Institute (NCI)· Source
Contact: Jacqueline T. Brown (principal investigator)
Recruiting
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
NCT06731270· Phase 2· Emory University· Source
Contact: Jennifer W Carlisle
Recruiting
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
NCT06287775· Phase 1/2· National Cancer Institute (NCI)· Source
Contact: Ticiana A. Leal (principal investigator)
Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
NCT06498635· Phase 3· National Cancer Institute (NCI)· Source
Contact: Onkar V. Khullar (principal investigator)
Recruiting
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source
Contact: Viraj Master (principal investigator)
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· Phase 3· NRG Oncology· Source
Contact: Jennifer M. Scalici (principal investigator)
Recruiting
Prevail Global Study
NCT06535854· Medtronic Vascular· Source
Contact: Pratik Sandesara (principal investigator)
Recruiting
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
NCT06699810· Phase 4· Emory University· Source
Contact: Priyathama Vellanki, MD, MS
Recruiting
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
NCT06006013· Phase 2· Emory University· Source
Contact: Wilena Session
Recruiting
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989· Phase 3· ECOG-ACRIN Cancer Research Group· Source
Contact: Dong M. Shin (principal investigator)
Active, not recruiting
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· Phase 3· NRG Oncology· Source
Recruiting
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
NCT06636734· Phase 2· Emory University· Source
Contact: Ardith Deshay
Recruiting
PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer
NCT06914999· Early phase 1· Emory University· Source
Contact: Nashwa M. Jarkas
Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682· Phase 2· SWOG Cancer Research Network· Source
Contact: Shirish M. Gadgeel (principal investigator)
Recruiting
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
NCT06337318· Phase 3· National Cancer Institute (NCI)· Source
Contact: Kristie A. Blum (principal investigator)
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806· Phase 3· National Cancer Institute (NCI)· Source
Contact: Kenneth Cardona (principal investigator)
Showing 50 of 198.